EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Treatment and clinical outcomes of patients with acute myeloid leukemia in Finland 2010–2020: A retrospective analysis of electronic health records

Juha Ranti, Hanna Pudas, Martta Ranta, Samuli Tuominen, Kristiina Uusi-Rauva, Johanna Lammela

European Journal of Haematology · 2024

DOI: 10.1111/ejh.14272 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Juha Ranti und 5 weiteren Autor:innen. Beteiligte Einrichtung: Turku University Hospital, Turku, Finland. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation, Electronic Health Records. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Our retrospective study (2010–2020) examined treatment patterns, outcomes, and healthcare resource utilization in Finnish acute myeloid leukemia (AML) patients. Data covered 153 patients diagnosed at Hospital District of Southwest Finland (HDSF) and 107 from other districts who underwent allogeneic stem cell transplantation (aSCT) at HDSF. Of the 153 patients, 56.2% received intensive chemotherapy (IC), while 43.8% deemed ineligible for IC received low‐intensity therapies or best supportive care (BSC). Median overall survival for IC patients was 31.2 months, compared to 5.3 months for those under azacytidine and 1.2 months on BSC. Majority (57.5%) of patients over 60 with intermediate/high European leukemia network risk had poor outcomes with IC and couldn't proceed to aSCT. These patients carried the highest costs and hospital resource use per patient month. Most common reasons for transplant ineligibility after IC were refractory disease and infection. Our data provides a comprehensive view on AML treatment landscape from a period when the latest treatment advancements were not yet accessible. The data describes patient groups with poor prognosis and increased healthcare burden, emphasizing the need to improve treatment practices and identify better ways to get more patients to transplant, in a rapidly evolving treatment landscape.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteHematopoietic Stem Cell TransplantationElectronic Health RecordsHumansFinlandRetrospective StudiesMaleFemaleMiddle AgedAgedAdultTreatment OutcomePrognosisYoung AdultAdolescentDisease ManagementAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyAged, 80 and over

Stichwörter der Autor:innen

acute myeloid leukemiabest supportive careeligible/ineligibleintensive chemotherapylow intensity therapystem cell transplantation

Autor:innen und Institutionen

  • Turku University Hospital, Turku, Finland.
  • AbbVie, Inc., Helsinki, Finland.
  • Medaffcon Oy, Espoo, Finland.

Zitieren

APA

Ranti, J., Pudas, H., Ranta, M., Tuominen, S., Uusi-Rauva, K., & Lammela, J. (2024). Treatment and clinical outcomes of patients with acute myeloid leukemia in Finland 2010–2020: A retrospective analysis of electronic health records. European Journal of Haematology. https://doi.org/10.1111/ejh.14272

Vancouver

Ranti J, Pudas H, Ranta M, Tuominen S, Uusi-Rauva K, Lammela J. Treatment and clinical outcomes of patients with acute myeloid leukemia in Finland 2010–2020: A retrospective analysis of electronic health records. European Journal of Haematology. 2024. doi:10.1111/ejh.14272

BibTeX
@article{Ranti2024,
  author = {Ranti, Juha and Pudas, Hanna and Ranta, Martta and Tuominen, Samuli and Uusi-Rauva, Kristiina and Lammela, Johanna},
  title = {Treatment and clinical outcomes of patients with acute myeloid leukemia in Finland 2010–2020: A retrospective analysis of electronic health records},
  journal = {European Journal of Haematology},
  year = {2024},
  doi = {10.1111/ejh.14272}
}
Kostenlos starten →